Publications by authors named "Abbracchio M"

White matter damage and subsequent demyelination significantly contribute to long-term functional impairment after ischaemic stroke. Identifying novel pharmacological targets to restore myelin integrity by promoting the maturation of oligodendrocyte precursor cells (OPCs) into new myelinating oligodendrocytes may open new perspectives for ischaemic stroke treatment. In this respect, previous studies highlighted the role of the G protein-coupled membrane receptor 17 (GPR17) as a key regulator of OPC differentiation in experimental models of brain injury, including ischaemic stroke.

View Article and Find Full Text PDF

Background And Purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron (MN) loss and consequent muscle atrophy, for which no effective therapies are available. Recent findings reveal that disease progression is fuelled by early aberrant neuroinflammation and the loss of oligodendrocytes with neuroprotective and remyelinating properties. On this basis, pharmacological interventions capable of restoring a pro-regenerative local milieu and re-establish proper oligodendrocyte functions may be beneficial.

View Article and Find Full Text PDF
Article Synopsis
  • The Concise Guide to PHARMACOLOGY 2023/24 offers a summarized overview of approximately 1800 drug targets and around 6000 interactions with 3900 ligands, mostly in a tabular format.
  • It focuses on selective pharmacology and includes links to an open access knowledgebase for more detailed drug information.
  • The guide divides drug targets into six major categories, providing essential summaries and guidance based on the latest pharmacological data available as of mid-2023, while serving as an official resource by the International Union of Basic and Clinical Pharmacology.
View Article and Find Full Text PDF

G protein-coupled receptor 17 (GPR17) and the WNT pathway are critical players of oligodendrocyte (OL) differentiation acting as essential timers in developing brain to achieve fully-myelinating cells. However, whether and how these two systems are related to each other is still unknown. Of interest, both factors are dysregulated in developing and adult brain diseases, including white matter injury and cancer, making the understanding of their reciprocal interactions of potential importance for identifying new targets and strategies for myelin repair.

View Article and Find Full Text PDF

With the umbrella term 'neurodevelopmental disorders' (NDDs) we refer to a plethora of congenital pathological conditions generally connected with cognitive, social behavior, and sensory/motor alterations. Among the possible causes, gestational and perinatal insults have been demonstrated to interfere with the physiological processes necessary for the proper development of fetal brain cytoarchitecture and functionality. In recent years, several genetic disorders caused by mutations in key enzymes involved in purine metabolism have been associated with autism-like behavioral outcomes.

View Article and Find Full Text PDF

GPR17, a G protein-coupled receptor, is a pivotal regulator of myelination. Its endogenous ligands trigger receptor desensitization and downregulation allowing oligodendrocyte terminal maturation. In addition to its endogenous agonists, GPR17 could be promiscuously activated by pro-inflammatory oxysterols and chemokines released at demyelinating lesions.

View Article and Find Full Text PDF

In the mature central nervous system (CNS), oligodendrocytes (OLs) provide support and insulation to axons thanks to the production of a myelin sheath. During their maturation to myelinating cells, OLs require energy and building blocks for lipids, which implies a great investment of energy fuels and molecular sources of carbon. The oligodendroglial G protein-coupled receptor 17 (GPR17) has emerged as a key player in OL maturation; it reaches maximal expression in pre-OLs, but then it has to be internalized to allow terminal maturation.

View Article and Find Full Text PDF

Characterization of new pharmacological targets is a promising approach in research of neurorepair mechanisms. The G protein-coupled receptor 17 (GPR17) has recently been proposed as an interesting pharmacological target, e.g.

View Article and Find Full Text PDF

Myelin is the lipidic insulating structure enwrapping axons and allowing fast saltatory nerve conduction. In the central nervous system, myelin sheath is the result of the complex packaging of multilamellar extensions of oligodendrocyte (OL) membranes. Before reaching myelinating capabilities, OLs undergo a very precise program of differentiation and maturation that starts from OL precursor cells (OPCs).

View Article and Find Full Text PDF
Article Synopsis
  • The Concise Guide to Pharmacology 2021/22 offers a streamlined overview of nearly 1900 human drug targets, focusing on selective pharmacology and organized mainly in tables for quick reference.
  • The guide serves as a reliable, citable resource that distills extensive online content while ensuring it reflects the status as of mid-2021, distinct from ongoing database updates.
  • Key pharmacological targets include G protein-coupled receptors, ion channels, and enzymes, with official nomenclature and references provided to assist further research and understanding.
View Article and Find Full Text PDF

In multiple sclerosis (MS), oligodendrocyte precursor cells (OPCs) are recruited to the site of injury to remyelinate damaged axons; however, in patients this process is often ineffective due to defects in OPC maturation. The membrane receptor GPR17 timely regulates the early stages of OPC differentiation; however, after reaching its highest levels in immature oligodendrocytes, it has to be downregulated to allow terminal maturation. Since, in several animal models of disease GPR17 is upregulated, the aim of this work was to characterize GPR17 alterations in MS patients.

View Article and Find Full Text PDF

Brain ageing is characterised by a decline in neuronal function and associated cognitive deficits. There is increasing evidence that myelin disruption is an important factor that contributes to the age-related loss of brain plasticity and repair responses. In the brain, myelin is produced by oligodendrocytes, which are generated throughout life by oligodendrocyte progenitor cells (OPCs).

View Article and Find Full Text PDF

Geoffrey Burnstock, one of the most talented and brilliant scientists of his generation, was born on the 10th of May 1929 in London and died on the 2ndof June 2020, aged 91, in Melbourne (Australia). Geoffrey Burnstock started his research studies with an interest in the nerves controlling the guts of guinea pigs, and discovered a completely unexpected and ubiquitous signalling system mediated via extracellular nucleotides (the "purinergic theory"), which revolutionized our understanding of how cells communicate between each other. He made the highly controversial discovery that ATP (adenosine triphosphate), a molecule well known to biochemists for its role as a source of energy inside cells, could also transmit signals between them.

View Article and Find Full Text PDF
Article Synopsis
  • Research highlights the potential of promoting new myelinating oligodendrocytes to aid recovery after stroke by studying microglia and macrophage roles.
  • Using GPR17-expressing OPCs in a mouse model, findings show that early activation of these immune cells supports OPC reactions and reduces myelin damage, but they eventually become dysfunctional over time.
  • Infusing microglial-derived extracellular vesicles can restore immune cell function and enhance OPC maturation, improving neurological outcomes, with tmTNF identified as a key factor in OPC differentiation.
View Article and Find Full Text PDF

One of the most substantial and established environmental risk factors for neurological and psychiatric disorders is stress exposure, whose detrimental consequences hinge on several variables including time. In this regard the gestational period is known to present an intrinsic vulnerability to environmental insults and thus stressful events during pregnancy can lead to severe consequences on the offspring's brain development with long-term repercussions throughout adulthood. On this basis, we investigated the long-lasting impact of prenatal stress exposure on the susceptibility to the experimental autoimmune encephalomyelitis (EAE), a well-established murine model of multiple sclerosis.

View Article and Find Full Text PDF

The international purinergic scientific community has lost its pioneer. Geoffrey Burnstock, born on the 10th of May 1929 in London, died on the 2nd of June 2020, aged 91, in Melbourne (Australia). Geoff was one of the most highly regarded scientists of his generation.

View Article and Find Full Text PDF
Article Synopsis
  • The GPR17 receptor, found on oligodendroglial precursors, is a promising target for developing treatments that promote myelin production in multiple sclerosis (MS).
  • Researchers screened over 1,000,000 compounds to find selective agents that can activate GPR17, going through a multi-step testing and refinement process.
  • One promising compound, galinex, was shown to significantly delay the onset of experimental autoimmune encephalomyelitis (EAE), supporting the effectiveness of their drug discovery approach for discovering new MS treatments.
View Article and Find Full Text PDF
Article Synopsis
  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that leads to the loss of motor neurons, closely associated with issues in oligodendrocytes and their precursors, which are crucial for repairing nerve insulation (myelin).
  • The function of GPR17, a receptor linked to oligodendrocyte maturation, was studied in ALS, revealing that its levels significantly rise in the spinal cords of ALS mouse models, correlating with oligodendrocyte degeneration.
  • Treatment with the GPR17 antagonist montelukast improved the differentiation of oligodendrocyte precursor cells in SOD1 ALS mice, suggesting new therapeutic strategies for ALS.
View Article and Find Full Text PDF

MicroRNAs are small post-transcriptional regulators that modulate gene expression by directly interacting with their target transcripts. Since the interaction between miRNAs and target mRNAs does not require a perfect match, one single miRNA can influence the expression of several genes and lead to a very broad array of functional consequences. Recently, we identified miR-125a-3p as a new regulator of oligodendrocyte development, showing that its over-expression is associated to impaired oligodendrocyte maturation.

View Article and Find Full Text PDF
Article Synopsis
  • MicroRNAs, specifically miR-125a-3p, have been found to significantly influence the development of glial cells, particularly oligodendrocytes, which are crucial for nerve cell support and myelination.
  • Inactive lesions of multiple sclerosis (MS) patients show increased levels of miR-125a-3p, suggesting a link between this microRNA and the disease's progression, as its regulation impacts oligodendrocyte precursor cells (OPCs).
  • Experiments indicate that high levels of miR-125a-3p hinder OPC maturation, while lowering its expression can speed up the remyelination process, highlighting potential therapeutic targets for improving recovery in demyelinating diseases.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how type 2 diabetes (T2D) affects the nigrostriatal dopaminergic system (NDS), which is crucial for motor control and may increase the risk of Parkinson's disease in diabetics.
  • It was found that while T2D did not change overall dopamine levels in the brain, it did reduce the ability to stimulate dopamine release in response to activities.
  • Two anti-T2D drugs, DPP-4 inhibitors and sulfonylureas, were effective in preventing these impairments, with DPP-4 inhibitors also showing potential benefits in reversing age-related cellular changes in the brain.
View Article and Find Full Text PDF

Remyelination, namely, the formation of new myelin sheaths around denuded axons, counteracts axonal degeneration and restores neuronal function. Considerable advances have been made in understanding this regenerative process that often fails in diseases like multiple sclerosis, leaving axons demyelinated and vulnerable to damage, thus contributing to disease progression. The identification of the membrane receptor GPR17 on a subset of oligodendrocyte precursor cells (OPCs), which mediate remyelination in the adult central nervous system (CNS), has led to a huge amount of evidence that validated this receptor as a new attractive target for remyelinating therapies.

View Article and Find Full Text PDF